Editas Medicine

Editas Medicine
Genome editing company
Gene Editing
CRISPR Technology
Genomic Medicine
Clinical Research
Rare Diseases
Open roles at Editas Medicine
1 open roles
Join Our Team
Recruiting
Remote
On-site
Full-time
3 months ago
Products and services

reni-cel
Gene Therapy
ED
EDIT-101
Gene Therapy
ED
EDIT-301
Cell Therapy
CR
CRISPR Gene Editing Platform
Technology Platform
ED
EDIT-201
Gene Therapy

In Vivo Gene Editing Medicines
Gene Therapy
ED
EDIT-103
Gene Therapy
IN
In Vivo Gene Editing Services
R&D Services
CR
CRISPR/Cas Gene Editing Platform
Platform Technology
EX
Ex Vivo Cell Engineering
R&D Services
EX
Ex Vivo Gene Editing Services
Research Services
EN
Engineered Natural Killer (eNK) Cell Platform
Cell Therapy
ED
EDIT-401
Gene Therapy
Leadership
CS
Charlene Stern
Executive Vice President & General Counsel
KB
Kevin Bitterman
Interim President
DRL
David R. Liu
Founder
FZ
Feng Zhang
Founder
Similar companies

Regeneron
Focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations int...
Westchester County, New York
10,001+ employees
Public
Valuation $76B
559 open jobs

BioNTech
Develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
Mainz, Germany
1,001-5,000 employees
Public
Valuation $21.7B
196 open jobs

Xaira
AI for drug discovery
San Francisco, CA
51-200 employees
Private
Valuation 2.1B

Boston Scientific
Leading company in the technology industry
Marlborough, Massachusetts
10,001+ employees
Public
Valuation $58B
1,004 open jobs

CRISPR Therapeutics
Leading company in the technology industry
Cambridge, Massachusetts, United States
201-500 employees
Public
Valuation $2.9B
14 open jobs
Latest updates
All
X
News
HN
YouTube
Editas Medicine shares edge higher after Q4 earnings and revenue top estimates - MSN
MSN
News
·
1 month ago
Attachment - GlobeNewswire
GlobeNewswire
News
·
1 month ago
Editas Medicine (NASDAQ:EDIT) Share Price Passes Above 50 Day Moving Average - Here's What Happened - MarketBeat
MarketBeat
News
·
1 month ago
Evercore Maintains Editas Medicine(EDIT.US) With Buy Rating, Raises Target Price to $15 - 富途牛牛
富途牛牛
News
·
1 month ago
Editas Medicine price target raised to $15 from $13 at Evercore ISI - TipRanks
TipRanks
News
·
1 month ago
Show 15 more
Total Views
0
Total Apply Clicks
0
Total Mock Apply
0
Total Bookmarks
0
Reviews
4.2
5 reviews
Work-life balance
4.0
Compensation
3.5
Culture
4.3
Career
2.8
Management
3.5
78%
Recommend to a friend
Pros
Supportive and collaborative team environment
Great work-life balance and flexible hours
Cutting-edge research opportunities
Cons
Limited career advancement opportunities
High expectations and stress levels
Disorganized management practices
Salary Ranges
38 data points
Director
Junior/L3
Director
1 reports
$195,000
total per year
Base
$150,000
Stock
-
$195,000
$195,000
Interview experience
39 interviews
Difficulty
3.4
/ 5
Duration
2-5w
Offer rate
35%
Experience
Positive 67%
Neutral 15%
Negative 18%
Interview process
1
Phone Screen
2
Technical Interview
3
Hiring Manager
4
Team Fit
Contact and location